iBio Inc. (IBIO)
| Bid | 1.14 |
| Market Cap | 11.75M |
| Revenue (ttm) | 375K |
| Net Income (ttm) | -19.3M |
| EPS (ttm) | 1.3 |
| PE Ratio (ttm) | 0.92 |
| Forward PE | -1.43 |
| Analyst | Buy |
| Ask | 1.24 |
| Volume | 311,102 |
| Avg. Volume (20D) | 622,859 |
| Open | 1.21 |
| Previous Close | 1.20 |
| Day's Range | 1.17 - 1.23 |
| 52-Week Range | 1.03 - 6.89 |
| Beta | 1.02 |
About IBIO
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing ...
Analyst Forecast
According to 3 analyst ratings, the average rating for IBIO stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 320.17% from the latest price.
Stock Forecasts
1 year ago · proactiveinvestors.com
iBio partners with AstralBio to develop obesity treatments using AI-driven platformiBio, an AI-driven drug developer, shares surged more than 120% after it announced it has entered into a collaboration agreement with private biotech firm AstralBio to discover, engineer and develop n...
